THE NOSE KNOWS

A New Zealand innovation is clearing the air for hayfever sufferers and revolutionising the $30 billion global nasal decongestant market.

- 

THE WARMER MONTHS don't just beckon with beach walks and long evenings. Many New Zealanders prepare themselves for sneezing, itching and blocked noses. Spring is the season of allergic rhinitis, commonly known as hayfever, for around 1.2 million Kiwis. Roughly 30-40% of the population experiences some form of seasonal allergy.

Sales of decongestants and antihistamines surge during these pollen-heavy months. Globally, the nasal decongestant market is valued at around $30 billion.

Goodair Nosebuds, a world-first, drug-free device developed in Auckland, are set to disrupt the status quo. Rather than masking symptoms with steroid sprays, nasal saline rinses or antihistamines, Goodair Nosebuds harness the nose's own natural defences to protect against congestion.